Galderma’s Aklief (trifarotene) Receives the US FDA’s Approval for the Treatment of Acne in 20 Years

 Galderma’s Aklief (trifarotene) Receives the US FDA’s Approval for the Treatment of Acne in 20 Years

Galderma’s Aklief (trifarotene) Receives the US FDA’s Approval for the Treatment of Acne in 20 Years

Shots:

  • The approval is based on two P-III study results assessing Aklief (trifarotene, qd) vs vehicle in 2,420 patients with moderate acne on the face and trunk
  • The P-III studies demonstrated reduction of inflammatory lesions as early as two weeks on the face and four weeks on the back, shoulders and chest compared to vehicle with well tolerated results
  • Aklief (trifarotene) Cream 0.005% is a topical treatment used for targeting retinoic acid receptor (RAR) gamma designed for of acne vulgaris in patients 9 years of age and older with its expected availability in Nov 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post